Cingulate Inc. 8-K

What Happened

• Cingulate Inc. (via its subsidiary Cingulate Therapeutics LLC) filed an 8-K disclosing an amendment to the employment agreement of Matthew N. Brams, Executive Vice President and Chief Medical Officer. The amendment, entered June 30, 2026 (effective January 1, 2026), extends Mr. Brams’ full-time employment trial period from June 30, 2026 to September 30, 2026.
• The company also issued a press release on July 2, 2026 announcing that Cingulate was selected for membership in the Russell 3000E® Index.

Key Details

• Employment amendment date: June 30, 2026; effective date of original agreement: January 1, 2026.
• Trial period extension for CMO Matthew N. Brams: from June 30, 2026 to September 30, 2026.
• Index announcement date: July 2, 2026; selection to the Russell 3000E® Index was disclosed via press release (Exhibit 99.1).

Why It Matters

• Executive continuity: Extending the trial period clarifies that Mr. Brams’ full-time status is pending through September 30, 2026, which may affect near-term leadership stability in clinical and medical programs.
• Market visibility: Inclusion in the Russell 3000E index increases the company’s visibility to investors and may lead to changes in trading volume or passive fund ownership as index providers and funds adjust holdings. This is a non-financial development that could influence investor attention and liquidity.